Agoracom Blog Home

Posts Tagged ‘#Revenue’

CLIENT FEATURE: Applied BioSciences $APPB – Leveraging Science Based Cannabinoid for Future Success $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 2:00 PM on Wednesday, August 14th, 2019
  • Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiatives
  • Purposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets

Corporate Highlights

  • Renewed strategy focused on leveraging endocannabinoid system to develop high-value products across three separate business units, including:
  • Biopharmaceuticals: goal to develop novel therapeutics to treat serious diseases across a range of therapeutic areas, including metabolic, peripheral neuropathy and progressive lung disease
  • CBD Products: multiple brands offering high-quality CBD products to the highest regulatory standards;
  • Bolstered leadership team with highly qualified individuals including Raymond W. Urbanski MD, PhD, as Chief Executive Officer, former business unit Chief Medical Officer at Pfizer Inc. and well-established industry leading expert with over 20 years of experience in clinical development, research and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology;
  • Appointed Martin Schroeder to the Scientific Advisory Board and as President of Applied BioPharma. Mr. Schroeder has over 30 years of experience in the pharmaceutical and biotech industries and has helped many biotech and pharmaceutical companies conduct search and evaluation of compounds and molecules;
  • Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot;
  • Commenced discussions regarding proposed scientific trials with two leading Universities specializing in Veterinary Medicine;
  • Announced the acquisition of Trace Analytics with over 65 years of combined experience in the global testing market for Cannabis and Hemp;
  • Partnered with Boxing Heavyweight Champion, Shannon “The Cannon” Briggs to launch Champ Organics, an athlete-focused cannabidiol (“CBD”) based health and wellness supplements product line that enhances training and recovery; and
  • Launched robust business development initiative to build biopharmaceuticals pipeline.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected] Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

CLIENT FEATURE: Applied BioSciences $APPB – Leveraging Science Based Cannabinoid for Future Success $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 10:46 AM on Thursday, August 8th, 2019
  • Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiatives
  • Purposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets

Corporate Highlights

  • Renewed strategy focused on leveraging endocannabinoid system to develop high-value products across three separate business units, including:
  • Biopharmaceuticals: goal to develop novel therapeutics to treat serious diseases across a range of therapeutic areas, including metabolic, peripheral neuropathy and progressive lung disease
  • CBD Products: multiple brands offering high-quality CBD products to the highest regulatory standards;
  • Bolstered leadership team with highly qualified individuals including Raymond W. Urbanski MD, PhD, as Chief Executive Officer, former business unit Chief Medical Officer at Pfizer Inc. and well-established industry leading expert with over 20 years of experience in clinical development, research and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology;
  • Appointed Martin Schroeder to the Scientific Advisory Board and as President of Applied BioPharma. Mr. Schroeder has over 30 years of experience in the pharmaceutical and biotech industries and has helped many biotech and pharmaceutical companies conduct search and evaluation of compounds and molecules;
  • Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot;
  • Commenced discussions regarding proposed scientific trials with two leading Universities specializing in Veterinary Medicine;
  • Announced the acquisition of Trace Analytics with over 65 years of combined experience in the global testing market for Cannabis and Hemp;
  • Partnered with Boxing Heavyweight Champion, Shannon “The Cannon” Briggs to launch Champ Organics, an athlete-focused cannabidiol (“CBD”) based health and wellness supplements product line that enhances training and recovery; and
  • Launched robust business development initiative to build biopharmaceuticals pipeline.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected] Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

Applied BioSciences $APPB Provides Corporate Update and 2019 Business Outlook $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:40 AM on Tuesday, July 30th, 2019

Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiatives

Purposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets

Multiple expected near-term value driving milestones

BEVERLY HILLS, CA / ACCESSWIRE / July 30, 2019 / Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today provided a corporate update and business outlook for the remainder of 2019.

Corporate Highlights

  • Renewed strategy focused on leveraging endocannabinoid system to develop high-value products across three separate business units, including:
  • Biopharmaceuticals: goal to develop novel therapeutics to treat serious diseases across a range of therapeutic areas, including metabolic, peripheral neuropathy and progressive lung disease
  • CBD Products: multiple brands offering high-quality CBD products to the highest regulatory standards;
  • Bolstered leadership team with highly qualified individuals including Raymond W. Urbanski MD, PhD, as Chief Executive Officer, former business unit Chief Medical Officer at Pfizer Inc. and well-established industry leading expert with over 20 years of experience in clinical development, research and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology;
  • Appointed Martin Schroeder to the Scientific Advisory Board and as President of Applied BioPharma. Mr. Schroeder has over 30 years of experience in the pharmaceutical and biotech industries and has helped many biotech and pharmaceutical companies conduct search and evaluation of compounds and molecules;
  • Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot;
  • Commenced discussions regarding proposed scientific trials with two leading Universities specializing in Veterinary Medicine;
  • Announced the acquisition of Trace Analytics with over 65 years of combined experience in the global testing market for Cannabis and Hemp;
  • Partnered with Boxing Heavyweight Champion, Shannon “The Cannon” Briggs to launch Champ Organics, an athlete-focused cannabidiol (“CBD”) based health and wellness supplements product line that enhances training and recovery; and
  • Launched robust business development initiative to build biopharmaceuticals pipeline.

“Over the course of my academic and pharmaceutical career, I have developed a keen interest in the benefits of cannabinoids and their ability to address a wide range of disease states. I saw a great deal of potential in Applied’s science-based approach to the endocannabinoid system, which ultimately drove me to join at what I believe is a pivotal time in the Company’s history. Now with the right team in place and a renewed focus on our corporate and clinical strategies, I believe we have the potential to drive value for all stakeholders and impact areas of significant unmet need in established and rapidly growing markets,” commented Dr. Raymond Urbanski, Chief Executive Officer. “As we look towards the rest of 2019, we remain focused on the critical importance of taking the necessary steps to build a solid foundation from which we can launch future expansion and growth. With all our strategic approaches in place, we believe we are well-positioned to unlock the full potential of Applied BioSciences.”

Applied BioPharma

The Applied BioPharma business unit is focused on the development and commercialization of novel therapeutics to treat serious diseases by leveraging industry leading pipeline of endocannabinoid system-targeted drug candidates.

The Company is actively seeking in-license opportunities with the goal of developing an industry leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas. The Applied management team expects to announce at least one in-licensing agreement before year end.

Applied Products

The Applied Products business unit currently consists of eight different brands of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-US countries. The Company’s portfolio currently includes consumer, animal health, women’s health and sports medicine products.

Applied Products operates under a differentiated approach to quality and regulatory practices within the industry, which it believes well-positions them to be leaders in the market and access the significant opportunity for revenue generation. All CBD products utilize the most proven and effective production methods to ensure the highest quality output. The Company’s Full Spectrum products are made using CO2 Extraction, which allows for the proper retention of cannabinoids and terpenes vs a distillate, and a winterization process. Applied’s THC Free products are CBD Isolate infused. This isolation process leaves behind pure pharmaceutical grade CBD only, ensuring the highest quality is achieved. Additionally, the Company’s Nano CBD Isolate products use a specialized Nano-Particulizer, a process which creates a pure nano-molecule.

“The CBD industry continues to be of great interest among the medical and investment community. We have seen rapid growth and continue to witness advancements in the space, however current products on the market are not high quality or are not actually what the label claims them to be. Our team sees room for significant improvement and believe we have a competitive advantage by offering high-quality products through our differentiated approach,” said Scott Stevens, Founder and Chairman of the Board.

Trace Analytics, Inc.

Trace Analytics Inc., a majority owned subsidiary of Applied, is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology. The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

The Company is actively establishing a global medical and consumer platform and multiple brands through creating a platform to partner and invest in various segments in the consumer industry and establish key exclusive strategic alliances which serve to accomplish the task of becoming the market leader. For more information, please visit: http://traceanalytics.com

Upcoming Milestones Expected to Drive Value

  • In-license product candidates to build robust pipeline for the Applied BioPharma division;
  • Explore strategic options for non-dilutive funding with Trace Analytics;
  • Successfully execute overall strategy of the Company and Business Development efforts;
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company; and
  • Uplist to a National Exchange.

Dr. Urbanski concluded, “Our priority moving forward is to successfully execute our corporate strategy. We continue to make significant steps to raise the awareness of the Company with multiple stakeholders in the investment community as well as a number of strategic partners. Additionally, we have embarked on a formalized investor relations and corporate communications strategy to continue building off the momentum and firmly believe this will provide us with the opportunity to enhance the profile of Applied BioSciences and ultimately position us to uplist to a National Exchange. We look forward to continue providing you with updates as we execute our strategies in place.”

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics / biopharmaceuticals and delivering high-quality CBD products as well as state-of-the-art testing and analytics capabilities to our customers.

Applied BioSciences is focused on, testing and analytics, consumer and OTC brands, and partnership opportunities in the medical, health and wellness, and nutraceuticals. The Company has several strategic partnerships currently in place and is actively pursuing additional partnerships and other strategic growth opportunities. For more information, visit the Company’s website.

Investor and Media Contact:

[email protected]
(833) 475-8247

SOURCE: Applied BioSciences Corp.

Applied BioSciences $APPB Announces Two Consecutive Quarters Posting Record Revenues for FY Ended March 2019 $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:24 AM on Wednesday, July 24th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • FY 2019 revenue of $707,062; a 258% increase from the previous fiscal year with Q4 revenue for the Company of $234,553, representing a 1202% increase from Q4 FY 2018;
  • Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot
  • Appointed Raymond W. Urbanski MD, PhD as Director and CEO;
    Added 3 PhDs and 5 scientists to its operational team;
    Launched the first Organic Human Quality Pet Treats under the HerbalPet bran

Los Angeles, California–(Newsfile Corp. – July 24, 2019) – Applied BioSciences Corp. (OTCQB: APPB), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, as well as testing and analytics, and pet health industries, today announced that it has achieved a record revenue quarter with multiple milestones for the fiscal year ended March 31, 2019. The Company has continued to make strategic investments in select brands and companies believed to be innovators in the consumer space. The investment remains on the balance sheet under “Equity Investments,” however the Company has begun a strategic review of options for the remaining equity stake.

Q4 FY 2019 Financial and Operational Highlights

  • FY 2019 revenue of $707,062; a 258% increase from the previous fiscal year with Q4 revenue for the Company of $234,553, representing a 1202% increase from Q4 FY 2018;
  • Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot;
  • Started initial pharmacokinetic safety study with a leading firm in the veterinary space;
  • Commenced discussions regarding proposed scientific trials with two leading Universities specializing in Veterinary Medicine; and
  • Announced the acquisition of Trace Analytics with over 65 years of combined experience in the global testing market for Cannabis and Hemp.

“Applied BioSciences’ results in the fourth quarter mark another record revenue quarter and solid revenue acceleration in our core products businesses. This has led to a historic year in a dynamic and rapidly evolving and growing space. We look forward to providing a corporate update and 2019 business outlook to the investor community on our strategy, milestones and continued progress in the near term,” stated Dr. Raymond W. Urbanski, CEO of Applied BioSciences.

Subsequent to Q4 2019

  • Appointed Raymond W. Urbanski MD, PhD as Director and CEO;
  • Added 3 PhDs and 5 scientists to its operational team;
  • Launched the first Organic Human Quality Pet Treats under the HerbalPet brand; and
  • Appointed Martin Schroeder to the Scientific Advisory Board and as President of Applied BioPharma. Mr. Schroeder has over 30 years of experience in the pharmaceutical and biotech industries and has helped many biotech and pharmaceutical companies conduct search and evaluation of compounds and molecules.

“Applied BioSciences continues to be at the forefront of the evolving consumer and testing market, using organically grown plants, without pesticides or herbicides as our main ingredient. As the Company, continues to expand our product lines it is important to know that our products have been thoroughly tested by trusted labs in the industry for chemicals, pesticides and any harmful materials. All our products are tested to ensure high-caliber and quality as well as overall safety. We will now be able to test our products in an expedited fashion as well as from third-party labs and continue to provide the highest standard of testing results and safety protocols on all our products,” commented JJ Southard, Vice President of Applied BioSciences Corp.

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the medical, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.

Trace Analytics Inc. is a leading cannabis and hemp science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology. The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Applied Biosciences – $APPB CBD Consumer Companies Seeing High Interest, But M&A Future Clouded In Smoke $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 9:07 AM on Tuesday, July 23rd, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
APPB : OTC
  • CBD-derived beauty, personal care and pet brands, among others, have made their way into national retail chains like Walgreens, Sephora and American Eagle Outfitters.
  • Industry experts say regulatory uncertainty and the young age of the category could result in more minority investments than buyouts in the near term.

With fewer restrictions than ever, buyers are increasingly curious about the smoking hot CBD-infused consumer products space, but industry experts say remaining regulatory uncertainty and the young age of the category could result in more minority investments than buyouts in the near term.

The inflection point for bringing CBD, or the non-psychoactive part of the cannabis plant, into the mainstream was the passage of the 2018 US Farm Bill last December, which lifted restrictions on selling hemp-derived products across state lines. Since then, CBD-derived beauty, personal care and pet brands, among others, have made their way into national retail chains like Walgreens, Sephora and American Eagle Outfitters.

CBD oil hemp products, Medicinal cannabis with extract oil in a bottle on a wooden table. Medical cannabis concept

CBD oil hemp products, Medicinal cannabis with extract oil in a bottle on a wooden table. Medical cannabis concept Getty

Michael Lux, a Denver-based Partner at accounting firm Crowe, said he expects strategic minority investments to make up the bulk of CBD’s activity over the next 6-12 months. Although many of the industry’s players are “growing like weeds,” he explained that most are younger than five years old and not ready to explore full exits.

Despite the category’s youth, Lux said interest from consumer packaged goods (CPG) companies has been “very high,” and noted that many of his firm’s CBD-based consumer clients have been approached for strategic investments, as well as research and retail partnerships.

However, one industry banker cautioned that “it will be a bit off” before the market can expect to see acquisitions from traditional CPG groups, particularly for ingestible products like beverages and edibles, since the Food and Drug Administration (FDA) is still working to create a regulatory framework for CBD.

Earlier this week, the FDA announced that it is expediting its effort to create clearer guidelines for CBD, which is believed to have healing property for a range of conditions, including inflammation and anxiety. The department plans to publish a report on its progress by early fall.

In the meantime, companies who operate in the personal care space, with products like CBD-infused topical creams, beauty products and tinctures, are more likely to receive strategic investments, said the banker and a second banker interviewed for this report. Both noted that regulators are more comfortable with non-digestible products, making them a less risky investment.

Canadian cannabis companies, many of which have dual listings on the Canadian and US stock exchanges, are especially likely to invest in US CBD brands in the near term, each of the sources said. They explained that these businesses provide entry into the US market without jeopardizing their US listings, since THC is still federally illegal in the US.

CBD stands for cannabiodil and lacks the psychoactive properties of THC (which stands for tetrahydrocannabinol). Both naturally occur in marijuana/hemp and the farm bill legalized hemp products with only low concentrations of THC.

Seattle-based Lazarus Naturals, which was founded in 2014 and sells CBD-based supplements and personal care products, is one such company. In an April interview with Mergermarket, CEO Sequoia Price-Lazarus said the business has received approaches from publicly-traded Canadian cannabis companies. Though not pursuing a sale, the executive said the company is considering raising up to $20 million in growth capital this year.

Cannabis producer Canopy Growth’s acquisition of London-based natural skincare company This Works in May was more evidence of hemp producers’ interest in the personal care space.

While some financial sponsors, such as Seattle-based Privateer Holdings, were built specifically to invest in CBD and cannabis brands, each of the sources said most US financial sponsors would be barred from investing in the category since most existing funds restrict investments in the space. Lux said he has “heard of a few” sponsors who are interested in raising CBD-friendly funds, but noted that this could take a significant amount of time.

Strategic buyers across a range of industries, including pharmaceuticals, consumer products and food and beverage, are expected to show interest in acquiring CBD brands once FDA regulations become more clear, but in the meantime, activity will be limited to minority investments, particularly from Canada, each of the sources agreed.

“I think people are still trying to figure out where this is going to go,” said Lux. “It’s an industry that didn’t exist 10 years ago and barely existed five years ago, and it sounds cliché, but the sky really is the limit here.”

SOURCE: By Emily Fasold , Forbes

https://www.forbes.com/sites/mergermarket/2019/07/22/cbd-consumer-companies-seeing-high-interest-but-ma-future-clouded-in-smoke/#533e55d25a0f

Applied Biosciences $APPB: U.S. CBD Market to Grow 700% Through 2019 $WMD.ca $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 9:00 PM on Saturday, July 20th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics.  As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
APPB : OTC
  • Brightfield Group 2019 U.S. CBD Market Report
  • Shifts across the U.S. CBD industry signal a seven-fold increase in the market
  • Bulk of growth coming from CVS, Walgreens, and Kroger entering the market and providing availability to consumers
  • 1.0% of CBD companies were in the top tier (with sales of $40+ million or being sold in greater than 1000 stores) while 92.9% of companies were in the low tier (with sales of <$1 million or being sold in 0-100 stores)

In their recent report, Brightfield Group, a leading market and consumer intelligence firm for the legal CBD and cannabis industries, uncovered numerous shifts across the U.S. CBD industry, signaling a seven-fold increase in the market. With hemp-derived CBD gaining in popularity – in line with health, wellness, and anti-pharma trends – and product availability and variety increasing, the market is on track to grow to $23.7 billion through 2023.

“The CBD market has been growing rapidly, but we will see unprecedented growth in 2019,” Brightfield Managing Director, Bethany Gomez, explains. “The bulk of this growth is coming from large retailers like CVS, Walgreens, and Kroger entering the market and providing that availability to consumers.”


Key highlights from the report:

  • Though they entered the market only this year, mass retail chains will eclipse all other channels in 2019, hosting 57% of sales this year
  • Although tinctures still dominate the market, driving 25% of sales, they are losing their lead as more mainstream consumer-friendly products surge
  • Topicals (17% of market) and skincare & beauty products (8%) have gained tremendous traction as mass retailers have signed on to carry these products first, since they are considered the safest bet under the current regulatory regime.
  • Natural food and smoke shop CBD revenues continue to grow and thrive – with increased uptake across the country and some level of saturation now that vendors feel more secure and confident carrying product. Notably, though the CBD market is no longer dominated by cannabis users, dispensaries and recreational shops have also seen an uptick in CBD-oriented traffic
  • 1.0% of CBD companies were in the top tier (with sales of $40+ million or being sold in greater than 1000 stores) while 92.9% of companies were in the low tier (with sales of <$1 million or being sold in 0-100 stores)

About Brightfield: Brightfield Group is a predictive market and consumer intelligence firm focused on the legal CBD and Cannabis industries. Their analytic solutions leverage data from millions of sources, enabling customers to get the most holistic view possible while drilling down into the fine details. They provide comprehensive, up-to-date, and actionable market and consumer insights that transform the best of research and technology into long-term business growth.
SOURCE: https://www.brightfieldgroup.com/press-releases/cbd-market-growth-2019

Applied Biosciences #CBD-based Functional Drinks Targeting Health Conscious Consumers $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 2:10 PM on Wednesday, July 17th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics capabilities to our customers.  As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
APPB : OTC
  • Cannabis-based concentrates, extracts, and edibles are becoming highly popular among consumers
  • Specifically, the edible and beverage marketplace is quickly gaining popularity due to the ease at which customers can use the products

NEW YORK, July 16, 2019 — Each year, more and more countries are moving towards approving cannabis use. In particular, medicinal cannabis is witnessing immense support as most of the countries looking to enter into the market space are more keen on the medical sector due to the therapeutic benefits associated with cannabis. However, several regions around the world have also either decriminalized or legalized the use of recreational cannabis in moderate amounts. For instance, Canada completely legalized adult-use cannabis in late 2018. On the other hand, countries such as Colombia and Spain have only decriminalized recreational use, allowing adults to possess up to a certain amount.

Moreover, the U.S. has given states the jurisdiction to legalize cannabis or keep the drug illicit. As a result, more than half the U.S. legalized cannabis for medical use, while a fifth of the nation, including the District of Columbia, allows for legal recreational usage. While the medical marketplace is much more globally prevalent, the recreational market is expected to overshadow the medical segment as the North American market continues to mature.

Additionally, as the recreational market continues to expand, consumers are also experiencing an influx of new products. Aside from traditional cannabis flower, consumers can now choose from a variety of products at dispensaries and retail stores. Now, cannabis-based concentrates, extracts, and edibles are becoming highly popular among consumers. Specifically, the edible and beverage marketplace is quickly gaining popularity due to the ease at which customers can use the products.

Furthermore, a large recreational user base exists for the edible and beverage market, and the industry is heavily being accelerated by the increasing demand for wellness products to treat a variety of health concerns. According to data compiled by Reports and Data, the global cannabis-based beverage market was valued at USD 1.57 Billion in 2018. By 2026, the market is expected to reach USD 5.04 Billion while exhibiting a CAGR of 15.4% during the forecast period.

The cannabis-infused edible and beverage market is expected to witness a strong increase in demand, particularly for beverages over the next several years. Canaccord Genuity analyst Bobby Burleson noted last year that beverages packed with CBD or THC ingredients can account for nearly 20% of the U.S. edible products markets by 2022, increasing from 6% in 2018. Burleson highlighted that the growing beverage industry is becoming an attractive investment opportunity for beer and soda makers and that data has shown that there is a direct correlation between alcohol and cannabis consumption.

A joint research conducted by the University of Connecticut, Georgia State University, and Universidad Del Pacifico discovered that counties located in medical marijuana states witnessed a 15% reduction in monthly alcohol sales. The conclusion of the study uncovered that cannabis and alcohol are both substitutes for one another, meaning that they share the same target audience. The study also indicates that as more countries move towards cannabis legalization, more users will be inclined to shift over to the cannabis market. The shift has even prompted alcohol producers to enter into the cannabis industry to maximize its consumer base reach.

While alcohol beverage producers may look towards developing THC beverages, soda producers are looking to leverage CBD for health and wellness beverages. Soda producers are specifically focusing on CBD because of the consumer shifts from sugary drinks to more functional options. Regardless of the market type, Canaccord expects both the THC and CBD-based beverage markets in the U.S. to experience growth, as by 2022, Canaccord expects the demand for CBD beverages to reach USD 260 Million, while THC beverages are projected to reach USD 34 Million. “Interest has spiked from the beer industry on mounting evidence of a substitution relationship between cannabis and alcohol, while large soda companies increasingly view CBD as a natural fit within their strategically important wellness offerings,” Burleson wrote.

Read More: https://www.prnewswire.com/news-releases/cbd-based-functional-drinks-charm-health-conscious-consumers-300885358.html

CLIENT FEATURE: $APPB Prior Chief Medical Officer and Senior Director of Oncology Research and Development with Pfizer Inc. appointed APPB CEO $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 1:17 PM on Thursday, June 13th, 2019
  • Dr. Raymond  W. Urbanski MD, PhD, will work closely with the Board of Directors to set the vision and strategic direction of the company
  • Will establish organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. 
  • Overseeing the development of key products in the Applied BioSciences’ product pipeline
  • Directing development within the newly formed Applied BioPharma Division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected] Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

CLIENT FEATURE: Prior Chief Medical Officer and Senior Director of Oncology Research and Development with Pfizer Inc. appointed APPB CEO $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 11:41 AM on Monday, June 3rd, 2019
  • Dr. Raymond  W. Urbanski MD, PhD, will work closely with the Board of Directors to set the vision and strategic direction of the company
  • Will establish organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. 
  • Overseeing the development of key products in the Applied BioSciences’ product pipeline
  • Directing development within the newly formed Applied BioPharma Division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected] Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp

CLIENT FEATURE: $APPB Prior Chief Medical Officer and Senior Director of Oncology Research and Development with Pfizer Inc. Joins APPB as its CEO $PFE $WMD.ca $CGRW $APH.ca $GBLX $ACG.ca $ACB.ca $WEED.ca $HIP.ca

Posted by AGORACOM at 11:28 AM on Thursday, May 23rd, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Dr. Raymond  W. Urbanski MD, PhD, will work closely with the Board of Directors to set the vision and strategic direction of the company
  • Will establish organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. 
  • Overseeing the development of key products in the Applied BioSciences’ product pipeline
  • Directing development within the newly formed Applied BioPharma Division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp